Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone versus dexamethasone in hospitalized patients with COVID-19
ISRCTN44151777Phase 3Completed
- Sponsor
- Hospital do Rocio
- Start
- Aug 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methylprednisolone and dexamethasone in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hospital do Rocio. Primary endpoint: All-cause mortality at 28 days. Started Aug 2021; status: completed.
02
Drugs
methylprednisolonedexamethasone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN44151777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN44151777.